198 related articles for article (PubMed ID: 12889452)
1. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.
Butt AA
AIDS Read; 2003 Jul; 13(7):344-8. PubMed ID: 12889452
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.
Glesby MJ; Gerber JG
AIDS Read; 2003 Jul; 13(7):346-7. PubMed ID: 12889453
[No Abstract] [Full Text] [Related]
3. Hepatitis C and didanosine: risk of lactic acidosis.
Prescrire Int; 2005 Dec; 14(80):222-3. PubMed ID: 16400744
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside analogues and mitochondrial toxicity.
Fleischer R; Boxwell D; Sherman KE
Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks.
Prescrire Int; 2005 Dec; 14(80):226-9. PubMed ID: 16400748
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F; Carrat F; Pol S; Hor R; Rosenthal E; Goujard C; Morand P; Lunel-Fabiani F; Salmon-Ceron D; Piroth L; Pialoux G; Bentata M; Cacoub P; Perronne C;
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):47-52. PubMed ID: 16123681
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Bräu N
J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
[TBL] [Abstract][Full Text] [Related]
8. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
Moreno A; Quereda C; Moreno L; Perez-Elías MJ; Muriel A; Casado JL; Antela A; Dronda F; Navas E; Bárcena R; Moreno S
Antivir Ther; 2004 Feb; 9(1):133-8. PubMed ID: 15040545
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.
Laguno M; Milinkovic A; de Lazzari E; Murillas J; Martínez E; Blanco JL; Loncá M; Biglia A; Leon A; García M; Larrousse M; García F; Miró JM; Gatell JM; Mallolas J
Antivir Ther; 2005; 10(3):423-9. PubMed ID: 15918333
[TBL] [Abstract][Full Text] [Related]
10. Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo.
Bruno R; Sacchi P; Filice G
AIDS; 2003 Dec; 17(18):2674-5. PubMed ID: 14685062
[No Abstract] [Full Text] [Related]
11. [Fatal lactic acidosis in a patient infected by HIV and treated with stavudine and didanosine].
Mégarbane B; Goldgran-Tolédano D; Guérin JM; Baud F
Pathol Biol (Paris); 2000 Jun; 48(5):505-7. PubMed ID: 10949849
[TBL] [Abstract][Full Text] [Related]
12. [Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients].
Montes Ramírez ML; Rodríguez Zapata M
Rev Clin Esp; 2002 Oct; 202(10):543-5. PubMed ID: 12361553
[TBL] [Abstract][Full Text] [Related]
13. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Lafeuillade A; Hittinger G; Chadapaud S
Lancet; 2001 Jan; 357(9252):280-1. PubMed ID: 11214134
[TBL] [Abstract][Full Text] [Related]
14. [Difficulties of selecting patients to receive treatment against hepatitis C virus in patients with HIV coinfection].
Marcos Sánchez F; Albo Castaño MI; Martín Barranco MJ; Casallo Blanco S; Joya Seijo D; Del Valle Loarte P
Gastroenterol Hepatol; 2005; 28(6):363-4. PubMed ID: 15989822
[No Abstract] [Full Text] [Related]
15. Lactic acidosis and antiretroviral therapy: a case report and literature review.
Marra A; Lewi D; Lanzoni V; Wey SB; Odashiro LN; Gomes PS; Silva E
Braz J Infect Dis; 2000 Jun; 4(3):151-5. PubMed ID: 10934499
[TBL] [Abstract][Full Text] [Related]
16. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy.
Allaouchiche B; Duflo F; Cotte L; Mathon L; Chassard D
J Antimicrob Chemother; 1999 Jul; 44(1):137-8. PubMed ID: 10459826
[No Abstract] [Full Text] [Related]
17. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial toxic effects and ribavirin.
Salmon-Céron D; Chauvelot-Moachon L; Abad S; Silbermann B; Sogni P
Lancet; 2001 Jun; 357(9270):1803-4. PubMed ID: 11407389
[No Abstract] [Full Text] [Related]
19. Anti-HIV agents. Hepatitis C treatment and possible interactions with anti-HIV drugs.
TreatmentUpdate; 2004; 16(3):2-4. PubMed ID: 17216833
[No Abstract] [Full Text] [Related]
20. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
